|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2005-11-21
|
|
pubmed:abstractText |
A wide variety of tumors depend on the dysregulation of Bcl-2 family proteins for survival. The resulting apoptotic block can often provide a mechanism for resistance to anticancer treatments, such as chemotherapy and radiation. This current study evaluates the efficacy of combining systemically delivered Bcl-2 phosphorothioate antisense (Bcl-2 ASO) and radiation for nasopharyngeal cancer therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AuP Y BilliePY,
pubmed-author:BastianuttoCarloC,
pubmed-author:BussonPierreP,
pubmed-author:GilbertRalphR,
pubmed-author:GullanePatrickP,
pubmed-author:HuangDollyD,
pubmed-author:LiuFei-FeiFF,
pubmed-author:MocanuJoseph DJD,
pubmed-author:O'SullivanBrianB,
pubmed-author:SleepGillian TGT,
pubmed-author:YehWen-ChenWC,
pubmed-author:YipKenneth WKW
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
8131-44
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16299246-Animals,
pubmed-meshheading:16299246-Apoptosis,
pubmed-meshheading:16299246-Blood Vessels,
pubmed-meshheading:16299246-Cell Line, Tumor,
pubmed-meshheading:16299246-Cell Survival,
pubmed-meshheading:16299246-Combined Modality Therapy,
pubmed-meshheading:16299246-Female,
pubmed-meshheading:16299246-Fluorescein-5-isothiocyanate,
pubmed-meshheading:16299246-Humans,
pubmed-meshheading:16299246-Kidney,
pubmed-meshheading:16299246-Liver,
pubmed-meshheading:16299246-Mice,
pubmed-meshheading:16299246-Mice, Inbred BALB C,
pubmed-meshheading:16299246-Mice, SCID,
pubmed-meshheading:16299246-Microscopy, Fluorescence,
pubmed-meshheading:16299246-Nasopharyngeal Neoplasms,
pubmed-meshheading:16299246-Oligonucleotides, Antisense,
pubmed-meshheading:16299246-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:16299246-Radiation, Ionizing,
pubmed-meshheading:16299246-Tissue Distribution,
pubmed-meshheading:16299246-Treatment Outcome,
pubmed-meshheading:16299246-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
|
|
pubmed:affiliation |
Division of Applied Molecular Oncology, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
